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1. Introduction 
Alpha-dystroglycanopathies are a clinically and genetically heterogenous group of muscular 
dystrophies characterized by the reduced or absent glycosylation of alpha-dystroglycan 
(Muntoni et al., 2002). The hypoglycosylation of alpha-dystroglycan leads to decreased 
binding of its ligands, including laminin, agrin and perlecan in skeletal muscle and neurexin 
in the brain. The only known target for this type of glycosylation is alpha-dystroglycan, and 
together with other proteins of the dystrophin-glycoprotein complex it forms a link between 
extracellular matrix proteins and actin cytoskeleton. The clinical manifestations of alpha-
dystroglycanopathies are extremely variable, leading to a broad spectrum of phenotypes 
with limb-girdle muscular dystrophy (LGMD) without mental retardation delineating the 
milder end, and Walker-Warburg syndrome (WWS), muscle-eye-brain disease (MEB) and 
Fukuyama type congenital muscular dystrophy (FCMD) the severe end (Muntoni & Voit, 
2004) (Fig. 1). In most of the severe disorders, the eyes and the brain are affected in addition 
to congenital muscular dystrophy (CMD). Here, CMD is defined as onset of weakness 
prenatally or within the first 6 months of life, and LGMD is defined by later onset weakness, 
specifically after having acquired ambulation. The brain abnormalities are described as 
cobblestone lissencephaly; available pathological studies have demonstrated breeches of the 
glia limitans and over-migration of cortical neurons into the pial spaces. In WWS, the life-
span of patients is severely reduced and brain and eye abnormalities extremely severe 
(Dobyns et al., 1989); MEB and FCMD patients generally survive beyond infancy, ocular 
manifestations are usually milder in FCMD than in MEB (Fukuyama et al., 1981, Santavuori 
et al., 1989). To date, mutations in six genes which encode putative or confirmed 
glycosyltransferases have been identified in these autosomal recessively inherited disorders: 
Protein-O-mannosyl transferase 1 and 2 (POMT1 and POMT2), Protein-O-mannose 1,2-N-
acetylglucosaminyltransferase 1 (POMGnT1), Fukutin-related protein (FKRP), Fukutin (FKTN), 
and LARGE. Initially, each gene was associated with one syndrome (original phenotype) : 
POMT1 and POMT2 mutations giving rise to WWS; POMGnT1 mutations in patients with 
MEB; FKRP mutations in patients with congenital or late-onset muscular dystrophies 
(MDC1C and LGMD 2I); FKTN mutations in patients with FCMD; LARGE mutations in a 
patient with congenital muscular dystrophy type 1D (MDC 1D). Subsequently, mutation 
analysis in patients with milder or more severe syndromes within the dystroglycanopathy 
spectrum demonstrated allelic heterogeneity for different mutations in each of the 
dystroglycanopathy genes (Fig. 1). Null mutations in POMT1, POMT2, POMGnT1, FKRP, 
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FKTN and LARGE are associated with the most severe end of the clinical spectrum (WWS) 
of dystroglycanopathy, although not an absolute rule. 
 
Fig. 1. Gene mutations and clinical phenotypes of alpha-dystroglycanopathy 
2. Broader clinical spectrum and worldwide distribution of FKTN mutations 
A wide clinical spectrum is also evident for the FKTN mutations that were first reported in 
patients with FCMD and later in patients with WWS and in patients with LGMD 2M 
without mental retardation. FCMD is the second most common form of muscular dystrophy 
in Japanese population after Duchenne muscular dystrophy, but is seen very rarely in other 
population. The incidence of FCMD is 3-10 per 100,000 or nearly half that of Duchenne 
muscular dystrophy in the Japanese population, with a carrier frequency of one in 80 and is 
one of the most common autosomal recessive disorder in Japan (Fukuyama & 
Ohsawa,1984). FCMD patients have muscular dystrophy with severe mental retardation and 
a neuronal migration abnormality. Epilepsy and eye abnormalities are also frequently 
associated with FCMD. Toda et al. (1993) localized the FCMD locus to chromosome 9q31-33 
using genetic linkage analysis. They further defined the FCMD locus within a much smaller 
segment and also found evidence for strong linkage disequilibrium. Haplotype analysis 
using the markers D9S2105, 2107, and D9S172 indicated that most FCMD-bearing 
chromosomes in Japanese pedigrees were derived from a single ancestral founder (Toda et 
al., 1996). Most Japanese FCMD patients are homozygous for an ancestral founder mutation 
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in FCMD gene, which arose from the insertion of a 3 kb retrotransposon element into the 3’ 
untranslated region (UTR). Some patients are compound heterozygous, carrying another 
mutation in addition to the founder insertion, and leading to a more severe FCMD variant 
(Kobayashi et al., 1998a). The absence of patients with two non-founder mutations in Japan 
led to the hypothesis that this may be lethal, however since 2003 compound heretozygosity 
for many different mutations have been described in non-Japanese populations, including 
homozygosity for nonsense mutations. To date, at least 24 different FKTN mutations have 
been described in non-Japanese patients and phenotypes of these patients cover the entire 
range of alpha-dystroglycanopathies (Yis et al., 2011). 
We performed clinical studies in 41 families with FCMD examined between 1972 and 1992 
(Yoshioka & Kuroki, 1994). These patients were diagnosed on the standard criteria of FCMD 
described by Fukuyama et al. (1960). After the discovery of FCMD gene, we investigated 
gene mutations of these FCMD families (Yoshioka et al., 2008). Here, we at first describe the 
clinical studies performed until 1992 and later analysis of the genotype-phenotype 
relationship in FCMD. We then present Japanese CMD patients with alpha-
dystroglycanopathy with other gene mutations than FKTN and without any known gene 
mutation. In addition, we describe FKTN mutations outside Japan and compare them with 
Japanese FCMD patients. 
2.1 Japanese FCMD patients diagnosed on standard criteria between 1972 and 1992 
We performed clinical and genetic studies in 41 families with FCMD examined by us 
between 1972 and 1992 (Table 1) (Yoshioka & Kuroki, 1994). The diagnosis in these patients 
was established according to standard criteria described by Fukuyama et al. in 1960, which 
were, briefly, early onset hypotonia, joint contractures, severe mental retardation with 
occasional convulsions, and dystrophic abnormalities detected in the muscle biopsy 
specimen. Nine families (22%) had multiple affected children (“familial” FCMD). 
Unfortunately, two siblings in nine families had already died at the time of examination, 
and detailed clinical data other than their clinical diagnosis were therefore not available. The 
other 32 families had only one affected child (“sporadic” FCMD). Parental consanguinity 
was documented in 5 sporadic FCMD families and none of the familial cases. In total, 48 
patients, including 7 sib pairs, were evaluated with regard to maximum motor ability, 
mental and convulsion states, cranial CT or MRI findings, and EEG and ophthalmological 
data.  
 
 Total Familial Sporadic 
Number of families 
Consanguineous marriage 
Number of patients 
Male : female 
41 
5 
50 
22 : 28 
9 
0 
18 
5 : 13 
32 
5 
32 
17 : 15 
Table 1. Patients with Fukuyama-type Congenital Muscular Dystrophy (FCMD) [diagnosed 
according to standard criteria between 1972 and 1992, reproduced from Yoshioka & Kuroki, 
1994 ] 
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Fig. 2. Maximum motor ability in sib pairs and in familial and sporadic FCMD cases. The 
familial cases are numbered from 1 to 9. The members of each sib pair are connected by a 
line (Reproduced from Yoshioka & Kuroki, 1994). 
Three patients in our familial group but only one in our sporadic group showed no head 
control (“bedridden”), whereas a few ambulatory patients were seen in both groups (Fig. 2). 
Walk without 
help 
Stand after 
sitting 
Walk with help 
Creep 
Sit without help 
Roll over 
Head control 
Bedridden 
Number of families 
Male  :  female 
32 families 
17    :    15 
familial cases sporadic cases 
male female 
sib pairs 
family number 1-9 
覈 
覊 覘 覡 覩 
覬 
覯 
覓 覦 
9 families 
5    :   13 
www.intechopen.com
 
Alpha-Dystroglycanopathy 
 
7 
The familial FCMD patients showed relatively more severe motor disability than that in the 
sporadic FCMD patients. The maximum motor ability in most patients in both groups 
consisted of sitting without help. Although the speech ability varied between sibs and 
between families (Fig. 3), all patients showed moderate to severe mental retardation. As for 
convulsion states, about half of the patients had febrile or afebrile convulsions in both 
familial and sporadic groups. The convulsion state in 7 sib pairs was the same; both sibs in 3 
families had afebrile or febrile convulsions, while in 4 other families neither had convulsion. 
EEG showed paroxysmal discharges in three sibling pairs with convulsions, while in two of 
the other sibling pairs without convulsion a difference between siblings in EEG findings was 
apparent. Ophthalmologically, myopia, weakness of the orbicularis oculi, nystagmus, and 
optic nerve atrophy were common findings.  
 
Fig. 3. Speech ability in sib pairs and in familial and sporadic FCMD cases. Familial cases are 
numbered from 1 to 9, and the members of each sib pair are connected by a line (Reproduced 
from Yoshioka & Kuroki, 1994). 
Typical CT or MRI findings seen in FCMD were pachygyria or polymicrogyria of the fronto-
temporo-occipital regions, moderate dilatation of the lateral ventricles, especially posteriorly 
(colpocephaly), the abnormal signal in the cerebral white matter, and cerebellar cysts closely 
related to polymicrogyria (Fig. 4). However, in one family (S-family), the elder brother had 
the typical CT findings of FCMD, while the younger brother had marked dilatation of the 
lateral ventricles and an occipital encephalocele (Fig. 5). In addition, retinal detachment was 
present in the younger brother at birth, whereas in the elder brother it developed at 3 years. 
Our study revealed that FCMD patients ranged from ambulatory to bedridden, and some 
were able to form sentences while others uttered no meaningful words. Convulsions were 
found in about half of the patients. Hydrocephalus, encephalocele and retinal detachment 
were rare but true findings in FCMD. 
Speech sentences 
Could say words 
No meaningful 
words 
Number of families 
Male : female 
9   
5 : 13 
32 
17 : 15 
familial cases sporadic cases 
1
2
3 4 5
6 7 8
9
male female 
sib pairs 
family number 1-9 
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Fig. 4. Typical MR imaging in a FCMD patient aged 16 years. T1-(upper) and T2-(lower) 
weighted axial magnetic resonance images of the cerebellum (left) and cerebrum (right). 
Cerebral cortical dysplasia is mild, and numerous cysts closely related to polymicrogyria are 
seen in the cerebellum (Reproduced from Yoshioka et al., 2008). 
Based on these observations, we considered the clinical spectrum of FCMD to be much 
broader than previously described and to overlap with that of “mild” WWS and of MEB. 
2.2 Genetic study of S-family and further analyses of FCMD haplotype 
The FCMD locus was initially localized to chromosome 9q31-33 by genetic linkage analysis 
and homozygosity mapping (Toda et al., 1993, 1994).  
We analyzed one Japanese family (S-family) in which three siblings were affected with 
severe cerebral malformations in association with ocular anomalies and muscle disease 
(Yoshioka et al., 1992). Both parents were healthy and nonconsanguineous. The elder 
brother showed pachygyria on computed tomographic scan (Fig.5), retinal detachment in 
both eyes at the age of three years and dystrophic findings on a muscle biopsy. He was 
diagnosed clinically as having FCMD. The second pregnancy resulted in a male infant with 
anencephaly who survived for five minutes. Anencephaly was regarded as WWS with 
extreme brain abnormality. The third son exhibited at birth such characteristic features as 
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pachygyria, encephalocele, hydrocephalus, retinal detachment in both eyes, elevated serum 
creatine kinase activity, and arthrogryposis multiplex congenita which were consistent with 
WWS (Fig.5).  
 
Fig. 5. Cranial computed tomographic scans of two siblings of S-family. Left: the first son at 
the age of 5 months. Moderate dilatation of the lateral ventricles, especially posteriorly 
(colpocephalic) and pachygyria in the temporo-parietal region are shown. The low density 
area in the white matter is apparent. Right: the third son at birth. Marked dilatation of 
lateral ventricles and occipital encephalocele are evident (Reproduced from Yoshioka & 
Kuroki, 1994). 
Genetic analysis of this family was performed using polymorphic microsatellite markers 
flanking the FCMD locus (Toda et al., 1995). Genomic DNA was extracted from peripheral 
blood leukocytes of the parents, the first and the third siblings. Both patients (FCMD and 
WWS) shared exactly the same haplotype at seven marker loci spanning 16 cM and 
surrounding the FCMD locus. This suggests that both affected siblings should carry the 
same combination of FCMD alleles, each with a mutation. Since the patients of FCMD and 
WWS carry the identical combination of mutations on either allele of the FCMD locus, these 
clinical conditions are caused by the mutations in the same gene. The difference in clinical 
manifestations between FCMD and WWS may reflect the pleiotropy or variation of 
expressivity of the FCMD gene. 
Later, it was found that one specific haplotype was shared by 82% of FCMD chromosomes 
(Kobayashi et al., 1998b). These data supported the hypothesis of a single founder of this 
disease in the Japanese population. Moreover, eight haplotypes different from the founder’s 
were observed in FCMD chromosomes, indicating that eight different FCMD mutations in 
addition to the founder’s have occurred in Japan. Thereafter, it was clarified that a 
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retrotransposal insertion exists within this candidate-gene interval in all FCMD 
chromosomes carrying the founder haplotype. Two independent point mutations confirm 
that a mutation of this gene is responsible for the condition (Kobayashi et al., 1998a). 
Using new polymorphic microsatellite markers, we genotyped five CMD patients from four 
families including the S-family who had severe eye and brain anomalies, such as retinal 
dysplasia and hydrocephalus (Yoshioka et al., 1999). All patients were heterozygous for the 
founder haplotype of the FCMD gene. In S-family, the Japanese founder haplotype of the 
FCMD gene was derived from the patients’ mother and the haplotype, which cosegregate 
with nonsense mutation on exon 3 of the FCMD gene, was derived from their father (Fig. 6). 
Thus, two siblings were compound heterozygotes for FCMD. This showed severe eye 
anomalies such as retinal dysplasia or detachment and hydrocephalus could be included in 
the clinical spectrum of FCMD. The clinical spectrum of FCMD is much broader than 
previously presumed.  
㻰㻥S㻞㻝㻜㻡   㻝㻞㻤    㻝㻟㻜     㻝㻟㻤    㻝㻠㻜      
F㻯M㻰
㻰㻥S㻞㻝㻣㻜    㻞㻜㻝   㻞㻜㻝     㻝㻥㻞    㻝㻥㻢
㻰㻥S㻞㻝㻣㻝    㻝㻡㻟   㻝㻡㻣     㻝㻠㻣    㻝㻠㻣
㻰㻥S㻞㻝㻜㻣    㻝㻤㻟   㻝㻤㻟     㻝㻤㻟    㻝㻥㻟
㻰㻥S㻞㻝㻜㻡   㻝㻟㻜   㻝㻟㻤        㻝㻟㻜     㻝㻟㻤 
F㻯M㻰  
㻰㻥S㻞㻝㻣㻜   㻞㻜㻝   㻝㻥㻞        㻞㻜㻝     㻝㻥㻞
㻰㻥S㻞㻝㻣㻝   㻝㻡㻣   㻝㻠㻣        㻝㻡㻣     㻝㻠㻣
㻰㻥S㻞㻝㻜㻣   㻝㻤㻟   㻝㻤㻟        㻝㻤㻟 㻝㻤㻟
㻜 cM
㻜 cM
founder haplotype
with 㻟kb insertion
* *
nonsense mutation 
on exon 㻟
**
**
 
Fig. 6. Genotypes of S-family including two brothers at polymorphic microsatellite loci 
flanking the FCMD locus. This family is heterozygous for the founder insertion allele. The 
founder haplotype 138-192-147-183 for markers D9S2105-D9S2170-D9S2171-D9S2107 was 
derived from the patients’ mother and the haplotype 130-201-157-183, which cosegregated 
with nonsense mutation on exon 3 of the FCMD gene, was derived from their father. Thus, 
two brothers are compound heterozygotes for the disease (Reproduced from Yoshioka et al., 
1999). 
To investigate the distribution and origin of the founder insertion of FCMD, Watanabe et al. 
(2005) screened a total of 4,718 control DNA samples from Japanese and other Northeast 
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Asian population. Fifteen founder chromosomes were detected among 2,814 Japanese 
individuals. Heterozygous carriers were found in various regions throughout Japan, with an 
averaged ratio of 1 in 188, although previous reports have estimated the carrier frequency to 
be as high as 1 in 80 and the incidence to be 3-10/100,000 births (Fukuyama & Ohsawa, 
1984). In Korean populations, they detected one carrier in 935 individuals. However, they 
were unable to detect any heterozygous alleles in 203 Mongolians and 766 Mainland 
Chinese populations. These data largely rule out the possibility that a single ancestor 
bearing an insertion-chromosome immigrated to Japan from Korea or Mainland China and 
appear to confirm that FCMD carriers are rare outside of Japan. 
2.3 Phenotype-genotype relationship in FCMD after discovery of FCMD gene, FKTN 
Between 1994 and 2006, we diagnosed thirty-five patients with FCMD because they had the 
founder mutation homozygously or heterozygously, in Kobe City Pediatric and General 
Rehabilitation Center for the Challenged, Utano National Hospital, Shiga Medical Center for 
Children and Shizuoka Childrens’s Hospital (Yoshioka et al., 2008). Among these 35 
patients, we found 18 patients (eight boys and 10 girls) carrying a homozygous founder 
mutation (homozygous patients or homozygotes) and 17 patients (eight boys and nine girls) 
with a compound heterozygous mutation (heterozygous patients or heterozygotes). The 
range of follow-up was between one and 30 years (average 16.5 years) in homozygotes and 
between two and 19 years (average 12.8 years) in heterozygotes (Table 2).  
 
 Homozygous patients Heterozygous patients 
Number of patients 
Male : Female 
Follow-up period : mean 
     Range : years : months 
Maximum motor ability 
   Bedridden 
   Head control 
   Sit without help 
   Walk without help 
Mental status 
   No meaningful words 
   Speak single words 
   Speak in sentences 
Radiological findings 
   Pachygyria/polymicrogyria 
   Hydrocephalus 
   Cephalocele 
Ophthalmological findings 
   Retinal dysplasia 
   Retinal detachment 
18 
8 : 10 
16.5 years 
1 : 2~30 : 8 
 
2 
0 
15 
1 
 
2 
5 
11 
 
16 
0 
0 
 
0 
0 
17 
8 : 9 
12.8 years 
2 : 5~19 : 5 
 
8 
3 
4 
2 
 
11 
5 
1 
 
16 
2 
1 
 
7 
5 
Table 2. Clinical characteristics of FCMD patients diagnosed between 1994 and 2006 
(Reproduced from Yoshioka et al., 2008) 
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Genomic DNA was extracted from patients’ peripheral blood leukocytes. After digestion of 
genomic DNA with PvuII, Southern hybridization was performed using fEco8-1 as a probe 
to detect the 3 kb founder insertion in the DNA. If a patient had only one founder insertion 
(compound heterozygotes), we then screened all exons and flanking introns of the FKTN 
gene by polymeraze chain reaction direct sequencing to detect nonsense or missense 
mutations. Some members had been genotyped with polymorphic microsatellite markers as 
described previously (Kobayashi et al., 1998b). Each chromosome containing the 3 kb 
retrotransposal insertion was concordant with the founder haplotype represented as 138-
192-147-183 for markers D9S2105-D9S2170-D9S2171-D9S2107. 
Clinical characteristics in both groups are summarized in Table 2. Most homozygotes could 
sit without help and speak in sentences, while half of the heterozygotes were bedridden and 
most spoke no meaningful words. Typical CT or MRI findings of FCMD were seen in almost 
all cases. These included polymicrogyria within the cerebral cortex that was primarily in the 
frontal lobes (Figs.4 and 5). In the cerebellum, numerous intraparenchymal cysts closely 
related to the polymicrogyria were seen at the hemispheres (Fig.4). More severe cortical 
dysplasia was usually found in heterozygotes than in homozygotes. Hydrocephalus and 
cephalocele were found only in heterozygotes. In particular, ophthalmological findings 
showed a clear difference between the two groups; retinal dysplasia and detachment were 
only found in heterozygotes. 
In comparison with our study, systematic analysis of the FCMD gene in 107 unrelated 
patients by Kondo-Iida et al. (1999) revealed that 80 probands (75%) were homozygous for 
the 3 kb insertion, 25 (23%) were heterozygous, and two did not show the 3 kb insertion on 
either allele. In our study, however, the number of homozygotes and heterozygotes was 
almost the same. Although both groups included some sib pairs in our study, the number of 
probands was 16 for the homozygotes and 15 for the heterozygotes, which was also almost 
the same number. This result might be due to the small number of patients examined or a 
regional inclination in our study, as most of our patients lived in the western part (Kansai 
district) of Japan. 
According to the report by Kondo-Iida et al. (1999), among patients homozygous for the 
founder mutation, 91.5% showed milder (stand or walk with or without support) or typical 
(able to sit unassisted or to slide on buttocks) phenotypes, and only 2.5% of cases were 
classified as severe (could sit only with support or had no head control), while among 
patients with heterozygous for the founder mutation, 92% showed severe phenotypes. This 
was true in our study, as most homozygotes could sit without help, while half of the 
heterozygotes were bedridden. It was speculated that because the 3’-UTR of a gene affects 
the stability of its mRNA, the 3 kb sequence inserted in that portion of the FCMD gene may 
alter the secondary structure of FCMD mRNA and render it unstable. This notion is 
supported by RT-PCR analysis that revealed low levels of the expected amplification 
product occurred in patients who were homozygous for the founder mutation and lower 
than normal in patients heterozygous for the insertion and another mutation. In other 
words, chromosomes carrying the 3 kb insertion may merely produce a lower level of 
mature fukutin than normal and generate a relatively mild phenotype. On the other hand, 
nonfounder mutations, which include nonsense and missense mutations within the coding 
region, cause major structural changes in the fukutin protein and thus are likely to produce 
severe effects. 
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2.4 Seizure-genotype relationship in FCMD patients diagnosed between 1994 and 
2006 
Mutational analysis of 35 patients with FCMD is shown in Table 3. Each chromosome 
containing the 3 kb retrotransposal insertion was concordant with the founder haplotype 
represented as 138-192-147-183 for markers D9S2105-D9S2170-D9S2171-D9S2107. Eighteen 
patients were homozygous for the 3 kb insertion and 17 were heterozygous. Mutations other 
than the 3 kb insertion were identified seven of the 12 heterozygous patients examined. 
These included five patients with a nonsense mutation in exon 3, one patient with a 
missense mutation in exon 5 and one patient with a nonsense mutation in exon 8. Among 
five patients with mutation in exon 3, afebrile seizures were found in three patients. One of 
them showed intractable seizures and the other developed infantile spasms at age six 
months. Two of five patients with a mutation in exon 3 had no seizures during follow-up as 
they died at ages 2 and 5 years, respectively, raising the possibility that seizures could  
 
Haplotype  Location Mutation Type of 
mutation 
No. of 
patients 
Seizure status 
No. of patients 
Homozygous for the 
founder haplotype 
(138-192-147-183) 
3’ 
Untranslated 
region 
3 Kb 
insertion 
Instability 
of mRNA 
18 Afebrile seizures : 8 
Febrile seizures : 3 
No seizure : 7 
Heterozygous for the 
founder haplotype* 
   17 Afebrile seizures : 9 
Febrile seizures : 5 
No seizure : 3 
130-201-157-183 Exon 3 R47X Nonsense 5 Afebrile seizures : 3 
(Intractable : 1, 
infantile spasms : 1) 
No seizure : 2 
(died aged 2 and 5 
years) 
Not examined Exon 5 M133T Missense 1 Afebrile seizures : 1 
(Intractable : 1) 
Not examined Exon 8 R307X Nonsense 1 Febrile seizures : 1 
139-201-155-183 Unknown** Unknown Unknown 4 Afebrile seizures : 3 
(Intractable : 2) 
Febrile seizures : 1 
148-196-153-183 Unknown Unknown Unknown 1 Febrile seizures : 1 
128-199-155-183 Not done*** Not done Not done 1 Afebrile seizures : 1 
138-194-155-183 Not done Not done Not done 1 Febrile seizures : 1 
138-199-147-191 Not done Not done Not done 1 No seizure : 1 
138-196-147-191 Not done Not done Not done 1 Febrile seizures : 1 
Not examined Not done Not done Not done 1 Afebrile seizures : 1 
* Haplotypes other than the founder’s haplotype are shown below. 
** Sequence analyzed, but no mutation found 
*** Sequence analysis was not done yet. 
Table 3. Relationship between genotypes and seizures in FCMD patients (Reproduced from 
Yoshioka et al., 2008). 
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develop later. All five patients also showed severe clinical manifestations suggestive of 
WWS. One patient with a missense mutation in exon 5 had intractable complex partial 
seizures and severe psychomotor retardation. However, one patient aged six years with a 
nonsense mutation in exon 8 developed a febrile seizure at the age of four years four months 
and he had no EEG paroxysmal discharges. On the other hand, five of twelve patients who 
underwent sequence analysis of chromosome without the 3 kb insertion revealed no 
mutation within the coding region of FKTN. It is probable that the mutations in these alleles 
lie in regulatory regions such as promoter sequences or intronic sequences critical for 
alternative splicing. Among them, four patients showed the same haplotype, 139-201-155-
183, for markers D9S2105-D9S2170-D9S2171-D9S2107 and showed severe phenotypes. In 
addition, two of them had intractable seizures. 
It is interesting that in this study seven of 18 (39%) homozygous and three of 17 (18%) 
heterozygous patients had no seizures during follow-up. Although two of our heterozygotes 
without seizures died at ages 2 and 5 years, respectively, all homozygotes without seizures 
were older than four years and two patients were over 30 years of age. 
In addition, some had only febrile seizures throughout their life. Antiepileptic drugs were 
prescribed for half of the FCMD patients and no intractable seizures were observed in 
homozygotes. These facts showed that seizures occurring in FCMD patients were not 
always severe. Milder cortical dysplasia was suggested in FCMD, especially in 
homozygotes.  
From these observations, it was concluded that mutational analysis of the FCMD gene could 
predict seizure prognosis. Heterozygotes usually developed seizures earlier than 
homozygotes and some heterozygotes showed intractable seizures. Special attention is 
necessary when treating epilepsy in heterozygotes. Mutational analysis other than the 3 kb 
insertion and haplotype analysis may also help to predict seizure prognosis. 
2.5 Worldwide distribution of Fukutin mutation 
A Turkish geneticist who had read our paper (Yoshioka et al., 1999) asked us to analyze her 
CMD patient. This Turkish boy had characteristics of WWS. Parents were first cousins, and 
their first son was unaffected. The infant was born by cesarean section and weighed 2,700 
gm (25th percentile); his height was 50cm (50th percentile), and head circumference was 47 
cm (>97th percentile). Physical examination showed respiratory difficulties, central cyanosis, 
generalized hypotonia, hydrocephaly, bilateral buphthalmus, and cataracts. Rieger’s 
anomaly with iris atrophy and peripheral corneal adhesions was noticed. After cataract 
extraction of the right eye, ocular examination showed that the optic disc and the retina 
were hypoplastic. Cranial computed tomography showed hydrocephalus and cortical 
atrophy. After birth, this patient was supported by mechanical ventilation and died on the 
10th day. Neuropathological examination showed agyric hemispheres with polymicrogyria 
in several cortical segments and severe cortical disorganization in other segments. The 
ventricles released 600ml of cerebrospinal fluid. CMD was also seen, with variation in fiber 
size, and fibrosis. Immunohistochemical analysis showed greatly reduced staining for 
alpha-dystroglycan, but normal immunoreactivity for beta-dystroglycan in the skeletal 
muscle membrane. Serum creatine kinase levels were greatly elevated.  
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Genetic analysis of this family was performed. As expected, the patient had no Japanese 
founder insertion. We then screened all exons and flanking introns of the fukutin gene in the 
patient by polymerase chain reaction direct sequencing. We detected a homozygous 1bp 
insertion mutation, nt504(insT), in exon 5 of FKTN. This mutation causes a frameshift, 
resulting in a premature termination at codon 157. Both parents and the brother were 
heterozygous for this mutation. This is the first case worldwide in which a FKTN mutation 
has been found outside the Japanese population (Silan et al., 2003). 
Later, another Turkish boy with WWS phenotype was found to have a homozygous 
nonsense mutation in FKTN by the research group in the Netherlands (Beltran-Valero de 
Bernabe et al., 2003). The homozygous nonsense mutations within the coding region 
identified in two Turkish patients are predicted to cause a total loss of FKTN and are likely 
to produce a more severe phenotype which closely resembles WWS.  
Manzini et al. (2008) assembled a large cohort of patients with typical WWS (43 affected 
individuals from 40 families), drawn from Middle Eastern consanguineous families (16 
patients from 14 families) and from consanguineous and nonconsanguineous families from 
Europe and the Americas (27 cases). They found that 40% (16/40 families) of patients in their 
cohort carried mutations in the coding sequence of POMT1, POMT2, FKRP or FKTN with no 
POMGnT1 or LARGE mutations detected. FKTN and FKRP mutations in particular were much 
more common than previously suggested and were mostly identified in non-consanguineous 
patients of European descent (6/27 cases). All Ashkenazi Jewish patients in their group shared 
an identical haplotype at the FKTN locus and the same homozygous mutation c.1167_1168insA 
in exon 9 suggesting a founder effect in this population. They identified the carrier frequency of 
this mutation to be 0.7% in the Ashkenazi population in Israel, which will be extremely 
informative for genetic testing. A striking difference was observed in the geographic 
distribution of mutations, as Middle East families were mostly carriers of POMT1 mutations 
(35.7%, 5/14 families), while the most common cause of European/American cases was FKTN 
mutations (18.5%, 5/27 cases). An additional four USA Ashkenazi Jewish families with WWS 
were found to have a founder mutation in FKTN in this population (Chang et al., 2009). 
The cohort consisted of 92 unrelated individuals who showed hypoglycosylation of alpha-
dystroglycan at the sarcolemma by immunolabelling of skeletal muscle sections (80 patients) 
or had the clinical phenotype being highly suggestive of a alpha-dystroglycanopathy (12 
patients) was analyzed the mutation of genes related to alpha-dystroglycanopathy (Godfrey 
et al., 2007). Homozygous and compound heterozygous mutations were detected in a total 
of 31 probands (34 individuals from 31 families). Mutations in FKTN, typically associated 
with FCMD in Japan were found in six patients, none of whom are of Japanese origin. Only 
two of these patients had structural brain involvement; one patient affected by WWS and 
one by a MEB-FCMD phenotype. The remaining patients had no structural brain 
involvement; one case had CMD-no mental retardation and never acquired the ability to 
walk but has normal IQ and five individuals from three families have entirely normal 
intellect and a mild LGMD phenotype (LGMD 2M). Interestingly in the latter two of these 
families, a dramatic response to steroid therapy was noted (Godfrey et al., 2006).  
Vuillaumier-Barrot et al. (2009) reported four newly diagnosed Caucasian patients with 
FKTN mutations with a broad spectrum of phenotypes ranging from CMD associated with 
mental retardation to LGMD without central nervous system involvement. Two patients 
(two sisters) presented with CMD, mental retardation, and posterior fossa malformation 
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including cysts, and brain atrophy at brain MRI. The other two patients had normal 
intelligence and brain MRI. Sequencing of the FKTN gene identified three previously 
described mutations and two novel misssense mutations.  
In contrast to studies in Middle East families and European/American cases, a 10-year-old 
Korean boy with clinical features of FCMD was found to have homozygous Japanese insertion 
mutation (Lee et al., 2009). His parents were heterozygous carriers of the same mutation. He is 
the first genetically confirmed FCMD patient in Korea and the first non-Japanese patient 
carrying homozygous Japanese founder mutation. According to a large northeast Asian 
population study (Watanabe et al., 2005), the carrier frequency of 3-kb insertion mutation in 
Korean population is 1 in 935. Based on this observation, the incidence of FCMD by 3-kb 
insertion mutation is as low as 1 in 3,496,900 in Korea. On the other hand, the Japanese 
founder mutation was not detected in 766 mainland Chinese individuals (Watanabe et al., 
2005). However, the first FCMD case was reported in the Chinese population with a Japanese 
founder 3-kb insertion and the other copy with a known c.139C>T mutation (Xiong et al., 
2009). These Asian case reports emphasize the importance of considering the FKTN founder 
mutation for diagnostic purposes outside of Japan and suggest that segments of the Chinese, 
Korean and Japanese populations may have a recent common ancestor.  
2.6 Milder phenotype of FCMD  
The first indication that FKTN mutations may also cause a much less severe phenotype came 
from Murakami et al. (2006). They reported that six Japanese patients, all of whom were 
compound heterozygotes for FKTN founder mutation and a point mutation, had minimal 
muscle weakness, normal intellect and dilated cardiomyopathy. No mutation was found in 
the other responsible genes for alpha-dystroglycanopathy including FKRP, POMGnT1, 
POMT1, POMT2, and LARGE in these patients. Pathological findings in the biopsied skeletal 
muscles showed only minimal dystrophic changes, but have altered glycosylation of alpha-
dystroglycan and reduced laminin binding ability. Cardiac involvement is the most 
remarkable finding in these patients. All the patients showed dilated cardiomyopathy, and 
two of them had life-threatening, rapidly progressive cardiac insufficiency. Cardiac 
involvement is rarely described in patients with alpha-dystroglycanopathy except for some 
patients with LGMD 2I.  
Recently, milder cases of muscular dystrophy associated with FKTN mutations have also been 
reported in non-Japanese populations. Godfrey et al. (2006, 2007) reported on five non-
Japanese children from three families with normal intelligence and limb-girdle phenotype, 
caused by heterozygous point mutations in the FKTN gene. Puckett et al. (2009) reported an 
additional two brothers with a LGMD phenotype due to compound heterozygous FKTN 
mutation. These two brothers had elevated CK, mild muscle weakness and normal cognition. 
They lack any cardiac or ocular abnormalities. In addition to their mild clinical presentation, 
patients were also unique from an ethnic and molecular standpoint. Their father was of 
European descent and their mother, Japanese. The children, however, did not possess the 
common Japanese founder mutation. Rather, the brothers had two FKTN missense mutations, 
one of which, c527T>C, had not been previously reported. This is significant, as the vast 
majority of patients reported have been either homozygous or heterozygous for the common 
retrotransposon insertion. Despite the milder skeletal muscle phenotype of these patients and 
those reported by Murakami et al. (2006), muscle biopsies show a reduction in fully 
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glycosylated alpha-dystroglycan similar to severe forms of CMD, such as FCMD and MEB. 
This emphasizes that immunophenotype may correlate poorly with clinical severity. 
3. Japanese patients with alpha-dystroglycanopthy with other gene 
mutations than FKTN 
In Japan, FCMD is the most common form of CMD, whereas MEB, WWS, MDC1C and 
MDC1D were rarely seen. WWS has been observed in many population groups with a 
worldwide distribution (Dobyns et al., 1989). In contrast, both MEB and FCMD show striking 
founder effects. MEB was first described in Finland, where it is most prevalent, owing to a 
strong founder effect following by genetic drift (Santavuori et al., 1989, Haltia et al., 1997). 
Consequently, most MEB patients have come from a small, geographically isolated population 
in Finland, with few Caucasian exceptions. Taniguchi et al. (2003) examined 30 patients from 
various countries, including Japan and Korea, who were diagnosed as WWS, severe FCMD or 
MEB. Two Japanese patients were identified as compound heterozygotes of POMGnT1 
mutations. Severe hydrocephalus was observed prenatally by an ultrasonograph in both 
patients, and in one of them hydrocephalus required a ventriculo-peritoneal shunt at one year 
of age. Therefore, MEB patients may exist with a broader distribution than previously 
expected. Later, Matsumoto et al. (2005) performed detailed genetic and clinico-pathological 
analyses on 62 Japanese patients whose limb-muscle specimens showed altered glycosylation 
of alpha-dystroglycan. FKTN mutations were found in 54 patients (86%) examined, reflecting 
the most common form of CMD in Japan. In this study, the first patient with MDC1C (FKRP 
mutation) in oriental countries was found. Clinically, this patient showed severe muscle 
weakness from early infancy, marked elevation of serum CK level, calf hypertrophy, and 
normal intelligence; those are consistent with MDC1C. Further, the structural abnormality in 
the cerebellum was seen on brain MRI including disorganized folia and multiple cysts, those 
are commonly observed in FCMD/MEB. In addition, two MEB (POMGnT1 mutations) and 
one WWS (POMT1 mutation) were genetically confirmed. These studies show that patients 
with alpha-dystroglycanopathy in Japan have not only FKTN mutations but also have 
mutations of other genes such as POMT1, POMT2, POMGnT1 and FKRP. Molecular genetic 
studies have been helpful in defining subgroups of CMD. 
4. CMD patients without known gene mutations of alpha-dystroglycanopathy 
We studied a Japanese CMD patient with brain abnormalities without FKTN mutation using 
immunohistochemical analysis of dystrophic muscle and full mutational analysis of 
POMGnT1 and FKRP genes (Yoshioka et al., 2004).  
Hypotonia and generalized muscle weakness became apparent during the first year of life. 
Consanguineous marriage was not noted. He obtained head control at 4 months, rolled over 
at 9 months, learned to sit unsupported at 12 months, crept at 19 months and stood with 
support at 26 months of age. At 4 years he could walk with the short leg braces using walker 
and speak two-word’s sentences. Serum creatine kinase levels were markedly elevated 
(2,776 IU/L, normal range＜130 IU/L ). Brain MRI showed thick and bumpy cortices with 
shallow sulci and abnormal white matter changes (Fig. 7). Ophthalmologically, he had no 
abnormalities. Immunohistochemical analysis showed reduced staining of alpha-
dystroglycan, while expression of merosin and beta-dystroglycan was normal (Fig. 8). 
Sequence analysis of POMGnT1 and FKRP revealed no mutation. 
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Fig. 7. MR imaging at 15 months of age (the upper line) and 26 months of age (the lower 
line) on T2-weighted sequences. The cerebral white matter shows symmetric high intensity, 
which decreases with age (Reproduced from Yoshioka et al. , 2004). 
 
Fig. 8. Immunohistochemistry. Transverse serial frozen sections of skeletal muscle biopsies 
from the patient were immunostained with antibodies against alpha-dystroglycan (A), beta-
dystroglycan (B), and laminin alpha-2 (merosin) (C). Note that beta-dystroglycan and 
laminin alpha-2 were present but alpha-dystroglycan was absent in sarcolemma of muscle 
fibers. Scale bar=20 micrometer (Reproduced from Yoshioka et al.,2004).  
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From these observations, this CMD patient seemed to belong to alpha-dystroglycanopathy. 
However, sequence analysis of FKTN, POMGnT1 and FKRP showed no mutations. Although 
analyses of POMT1, POMT2 and LARGE are necessary, there seems to be still many CMDs 
whose causative genes are unknown. We previously reported these patients including this 
case as a variant of CMD (Yoshioka et al., 2002). 
Among their 62 Japanese patients with alpha-dystroglycanopathy, Matsumoto et al. (2005) 
found four patients with no mutation in the known genes associated with glycosylation 
defects of alpha-dystroglycan. They were clinically diagnosed to have MEB or WWS. All 
four patients showed severe mental retardation, hypotonia from early infancy, and eye 
involvements. Brain MRI displayed type II lissencephaly, enlarged lateral ventricles, and 
hypoplastic brainstem and cerebellum. In the skeletal muscles, three patients who were 
clinically diagnosed as WWS showed severe dystrophic changes with marked fibrous tissue 
involvement. However, one patient who was clinically diagnosed as MEB showed only mild 
myopathic changes in his muscle.  
It was true in non-Japanese patients with alpha-dystroglycanopathy. Although 31 among 92 
probands (34%) with alpha-dystroglycanopathy had homozygous and compound 
heterozygous mutations in the known genes, a large number of remaining patients with 
clinico-pathological features indistinguishable from the ones with mutations were not found 
to have mutations in any of the genes studied (Godfrey et al., 2007). More, as yet undefined, 
genes are likely to be involved in the pathogenesis of the alpha-dystroglycanopathies. The 
identification of these genes may provide additional information on the pathway of 
glycosylation of alpha-dystroglycan. 
5. Conclusion 
Defects in genes responsible for altered glycosylation of alpha-dystroglycan cause a group 
of muscular dystrophies that are variably associated with central nervous and eye 
abnormalities, known as alpha-dystroglycanopathies. These comprise FCMD, MDC1C and 
1D, WWS, and MEB. Mutations have been reported in six putative or demonstrated 
glycosyltransferases; FKTN, FKRP, LARGE, POMT1, POMT2, and POMGnT1. Although each 
disorder was initially associated with one gene, it has recently been shown that the 
spectrum of phenotypes is broader than previously thought, and all these syndromes can be 
associated with mutations in any of the six genes known to be involved in alpha-
dystroglycan glycosylation (Fig. 1).  
A wide clinical spectrum is also evident for the FKTN mutations that were first reported in 
patients with FCMD, and later also in patients with WWS, and in patients with LGMD. 
FCMD is most frequent in Japan, and relatively homogenous phenotype. The strikingly high 
prevalence of FMD among the Japanese appears to result from the initial founder effect, 
whose expansion occurred in relative isolation. Most FCMD-bearing chromosomes in Japan 
are derived from a single ancestral founder who lived a few thousands years ago. Seventy-
five percent of Japanese patients are homozygous for the ancestral mutation and have a 
relatively milder phenotype than patients who are compound heterozygous for the ancestral 
mutation and another mutation. The Japanese founder 3’ insertion mutation is therefore 
www.intechopen.com
 
Muscular Dystrophy 
 
20
regarded as a relatively mild mutation. The most common form of FCMD in Japan presents 
clinically with a combination of generalized muscle weakness, congenital structural brain 
malformations, seizures, decreased vision, and cardiomyopathy. Most patients are never 
able to walk independently and have moderate to severe cognitive delay. Japanese patients, 
who are compound heterozygous for the founder and another mutation, have much more 
severe WWS-like manifestations including hydrocephalus and microphthalmia.  
However, an increasing number of FKTN mutations are being reported outside Japan. To 
date, at least 24 different FKTN mutations have been described in non-Japanese patients and 
phenotypes of these patients cover the entire range of alpha-dystroglycanopathies (Yis et al., 
2011). Among 23 patients with CMD and mutations in the FKTN gene in non-Japanese 
populations, 10 patients had a WWS-like phenotype including severe brain and eye 
abnormalities, the remainder had a milder FCMD, MEB or LGMD phenotype. In addition to 
the Japanese founder mutation, the mutation c.1167insA in exon 9 has been found to be 
homozygous in seven non-consanguineous Ashkenazi Jewish families, with an estimated 
carrier frequency of the mutation of 0.7% in the Ashkenazi population in Israel. Affected 
patients in these Jewish families all had a severe WWS-like phenotype. 
The WWS phenotype caused by FKTN mutations is associated with the presence of two loss-
of-function mutations, although not an absolute rule. The relatively few reports of FKTN 
mutations in patients with mild phenotypes may be a result of ascertainment bias and the 
recent increase in the number of reports of such findings may result in increased mutation 
analysis in FKTN for such patients in the future. 
In summary, these results confirm that outside Japan, muscular dystrophy due to FKTN 
mutations is not as rare as initially supposed, and could be associated with a large spectrum 
of phenotypes, compared to the relatively homogenous phenotype in the Japanese 
population. 
Although alpha-dystroglycanopathy is still largely unknown, comprehensive mutation 
analysis in patients and genotype/phenotype correlation across the spectrum of disease 
caused by these genes may provide clues to gene function. Functional analysis in animal 
models will determine how these mutations affect the proteins. 
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revolutionized clinical research. Pathophysiology of the different muscular dystrophies, multifaceted functions
of the involved genes as well as efforts towards diagnosis and effective patient management, are also
discussed. Adding value to the book are the included reports on ongoing studies that show a promise for
future therapeutic strategies.
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